Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBurhop, Carstenen_US
dc.description.abstractIn this paper, we describe the emergence and evolution of pharmaceutical research at the German company E. Merck during the late 19th and early 20th century. Revolutionary changes in the scientific knowledge base, especially the rise of bacteriological research, and the market entry of dyestuff producers into pharmaceuticals made the re-organisation of pharmaceutical research during the 1890s a necessary corporate strategy. Consequently, Merck restructured its in-house research between 1895 and 1898. Moreover, the firm deepened its co-operation with universities and other outside inventors. Jointly and severally, the firm depended on outside inventors for the generation of new products, whereas in-house scientists improved the productive efficiency. Moreover, we show that a significant number of new products were launched between the late 1890s and 1905. During the following years, however, resource constraints restricted Merck's innovative capacity.en_US
dc.publisher|aMax Planck Inst. for Research on Collective Goods|cBonnen_US
dc.relation.ispartofseries|aPreprints of the Max Planck Institute for Research on Collective Goods|x2008,3en_US
dc.subject.keywordBusiness historyen_US
dc.subject.keywordpharmaceutical researchen_US
dc.subject.keywordcase studyen_US
dc.subject.stwPharmazeutische Forschungen_US
dc.subject.stwBusiness Historyen_US
dc.subject.stwDeutschland (bis 1945)en_US
dc.titlePharmaceutical research in Wilhelmine Germany: the case of E. Mercken_US
dc.type|aWorking Paperen_US

Files in This Item:
302.47 kB

Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.